Abstract |
From May 1991 to January 1996, 54 patients with advanced malignant melanoma were enrolled into a phase II trial testing the new nitrosourea cystemustine, administrated intravenously as a 15 min infusion every 2 weeks at 90 mg/m2 for three cycles followed by 60 mg/m2. Out of the 54 enrolled patients, 10 were Ineligible, leaving 44 fully evaluable patients (World Health Organization criteria). Twenty one patients had already received first-line palliative chemotherapy and/or immunotherapy. The median age was 62 years (range 30-74 years) and the median performance status was 0 (grade 0, 19 patients; grade 1, 21 patients; grade 2, 4 patients). Five patients with partial responses (lasting 16-29 weeks, mean duration 24 weeks), nine with stable disease and 28 showing progression were observed, giving an overall response rate of 11% (confidence interval 3.8-24.6%). Toxicity was mild and consisted mainly of neutropenia (39% grade III-IV), thrombocytopenia (42% grade III-IV); febrile aplasia was rare. Cystemustine administered to this schedule appears to have limited clinical activity and acceptable toxicity in untreated or second-line advanced malignant melanoma.
|
Authors | H Cure, P Souteyrand, R Ouabdesselam, H Roche, A Ravaud, M D'incan, P Viens, P Fargeot, M A Lentz, P Fumoleau, A Hanauske, P Chollet |
Journal | Melanoma research
(Melanoma Res)
Vol. 9
Issue 6
Pg. 607-10
(Dec 1999)
ISSN: 0960-8931 [Print] England |
PMID | 10661773
(Publication Type: Clinical Trial, Clinical Trial, Phase II, Journal Article)
|
Chemical References |
- Antineoplastic Agents
- Nitrosourea Compounds
- N'-(2-chloroethyl)-N-(2-(methylsulfonyl)ethyl)-N'-nitrosourea
- Dacarbazine
|
Topics |
- Adult
- Aged
- Antineoplastic Agents
(administration & dosage, adverse effects, therapeutic use)
- Combined Modality Therapy
- Dacarbazine
(therapeutic use)
- Female
- Humans
- Immunotherapy
- Male
- Melanoma
(drug therapy, pathology, secondary, therapy)
- Middle Aged
- Neoplasm Staging
- Nitrosourea Compounds
(administration & dosage, adverse effects, therapeutic use)
- Treatment Outcome
|